The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 6, 2012, Pages 559-565

  Van Ingen, Jakko ^a,b   Egelund, Eric F ^c   Levin, Adrah ^a   Totten, Sarah E ^a   Boeree, Martin J ^b   Mouton, Johan W ^b   Aarnoutse, Rob E ^b   Heifets, Leonid B ^a   Peloquin, Charles A ^c   Daley, Charles L ^a  

^a DEPARTMENT OF MEDICINE   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Drug resistance, bacterial; Mycobacteria, atypical; Mycobacterium avium complex; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMIKACIN; ANTIMYCOBACTERIAL AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; MOXIFLOXACIN; RIFABUTIN; RIFAMPICIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BODY MASS; COHORT ANALYSIS; DRUG DOSE REGIMEN; FEMALE; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADULT; AGED; AMIKACIN; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; CLARITHROMYCIN; COHORT STUDIES; COLORADO; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; RIFABUTIN; RIFAMPIN;

EID: 84866410786     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201204-0682OC     Document Type: Article

References (40)

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
2. van Ingen J, Boeree MJ, Kosters K, Wieland A, Tortoli E, Dekhuijzen PN, van Soolingen D. Proposal to elevate Mycobacterium avium complex ITS sequevar MAC-Q to Mycobacterium vulneris sp. nov. Int J Syst Evol Microbiol 2009;59:2277-2282.
3. Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010;182:977-982.
4. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL, Catanzaro A. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006;173:1283-1289.
5. van Ingen J, Bendien SA, de Lange WC, Hoefsloot W, Dekhuijzen PN, Boeree MJ, van Soolingen D. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 2009;64:502-506.
6. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47:2118-2124.
7. Deshpande D, Srivastava S, Meek C, Leff R, Gumbo T. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob Agents Chemother 2010;54:1728-1733.
8. Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med 1997;18:79-87.
9. van Ingen J, Levin A, Totten SE, Heifets LB, Peloquin C, Daley CL. Pharmacokinetics and drug susceptibility testing imply limited activity of current regimens for Mycobacterium avium complex disease. Am J Respir Crit Care Med 2011;183:A2404.
10. Somoskovi A, Mester J, Hale YM, Parsons LM, Salfinger M. Laboratory diagnosis of nontuberculous mycobacteria. Clin Chest Med 2002;23:585-597.
11. Hall L, Doerr KA, Wohlfiel SL, Roberts GD. Evaluation of the MicroSeq system for identification of mycobacteria by 16S ribosomal DNA sequencing and its integration into a routine clinical mycobacteriology laboratory. J Clin Microbiol 2003;41:1447-1453.
12. CLSI. Susceptibility testing of mycobacteria, Nocardiae, and other aerobic Actinomycetes: approved standard, 2nd ed. CLSI document M24-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
13. Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999;115:12-18.
14. Weiner M, Peloquin C, Burman W, Luo CC, Engle M, Prihoda TJ, Mac Kenzie WR, Bliven-Sizemore E, Johnson JL, Vernon A. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother 2010;54:4192-4200.
15. Cheng KL, Nafziger AN, Peloquin CA, Amsden GW. Effect of grape-fruit juice on clarithromycin pharmacokinetics. Antimicrob Agents Chemother 1998;42:927-929.
16. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:852-857.
17. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 1999;43:568-572.
18. Nix DE, Adam RD, Auclair B, Krueger TS, Godo PG, Peloquin CA. Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinb) 2004;84:365-373.
19. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004;38:1538-1544.
20. Peloquin C. Antituberculosis drugs: pharmacokinetics. In Heifets L, editor. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press; 1991. pp. 59-88.
21. Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 2004;23:243-255.
22. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781-3788.
23. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999;37:385-398.
24. Heifets LB, editor. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press; 1991.
25. Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Aralar P, Wu M, Young LS. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob Agents Chemother 2001;45:217-222.
26. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995;171:747-750.
27. Peloquin C, Berning SE. Evaluation of the drug interaction between clarithromycin and rifampin. J Infect Dis Pharmacother 1996;2:19-35.
28. Alffenaar JW, Nienhuis WA, de Velde F, Zuur AT, Wessels AM, Almeida D, Grosset J, Adjei O, Uges DR, van der Werf TS. Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. Antimicrob Agents Chemother 2010;54:3878-3883.
29. Cohen Y, Perronne C, Truffot-Pernot C, Grosset J, Vilde JL, Pocidalo JJ. Activities of WIN-57273, minocycline, clarithromycin, and 14- hydroxyclarithromycin against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother 1992;36:2104-2107.
30. Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 2009;10:381-401.
31. Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, Grimsey NJ, Cusens D, Coulter S, Cooper J, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011;121:3554-3563.
32. Zuckerman JM, Qamar F, Bono BR. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin North Am 2011;95:761-791.
33. Nijland HM, Ruslami R, Suroto AJ, Burger DM, Alisjahbana B, van Crevel R, Aarnoutse RE. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007;45:1001-1007.
34. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007;101:130-138.
35. Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003;124:1482-1486.
36. Shen GH, Wu BD, Hu ST, Lin CF, Wu KM, Chen JH. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010;35:400-404.
37. Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, Benson CA, Meek K, Siepman N, Craft JC. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997;11:311-317.
38. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Drug resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012;15:149-161.
39. Kobashi Y, Abe M, Mouri K, Obase Y, Kato S, Oka M. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother 2012;18:436-443.
40. Shafran SO, Deschenes J, Miller M, Phillips P, Toma E. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. N Engl J Med 1994;330:438-439.